Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dedication-1: Dose tapering and early discontinuation of pembrolizumab in advanced NSCLC
2024-516195-15-00Phase 3Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Overall survival rate at one year. Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-516195-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516195-15-00.